Life sciences venture firm 4Bio Capital has secured the biopharmaceutical company as the first strategic backer for its second fund.

Kyowa Kirin, a Japan-listed specialty pharmaceutical company, has committed an undisclosed amount for the second fund to be raised by 4Bio Capital, a UK-based venture capital firm targeting advanced medical therapies. 4Bio Capital had raised more than $50m for the first close of its 4Bio Ventures II fund in September 2019 having set a $150m…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.